The findings dispute the current understanding that tuberous sclerosis is exclusively attributed to genetic mutation. Tuberous sclerosis is a rare neurodevelopmental disorder characterized by ...

The tuberous sclerosis clinic accepts referrals from primary care providers and pediatric specialists from the United States and internationally. To make a referral, there are three options: Call us ...

References: Marinus pharmaceuticals announces topline results from phase 3 TrustTSC trial of oral ganaxolone in tuberous sclerosis complex and commences process to explore strategic alternatives.

BALTIMORE — A world-renowned University of Maryland Medical Center neurologist will lace up his running shoes and take to the streets for the New York City Marathon in honor of his patients.

A garden that was designed to raise awareness for the Tuberous Sclerosis Association has won a gold medal at the RHS Chelsea Flower Show. Jen Donnelly and Catherine Gibbon volunteer at Amersham ...

Patients present with a combination of symptoms that can include seizures, developmental delay, skin abnormalities and kidney disease,” said first and co-corresponding author Dr. Rituraj Pal, ...

SILVER SPRING, Md., May 7, 2025 /PRNewswire/ -- On May 15, the TSC Alliance® will join tuberous sclerosis complex (TSC) organizations around the world to observe the 13th Annual TSC Global ...

Tuberous sclerosis complex (TSC) afflicts as many as two million people around the world, affecting multiple organs, including lungs, brain, skin and kidneys. In about 80 percent of cases, it ...

Cytoskeletal F-actin of formaldehide fixed, acetone-extracted cells was stained with 7-nitrobenz-2-oxa-1,3-diazole(NBD)-phallacidin. Skin fibroblasts from apparently normal fetuses, children and ...

The criteria for considering surgery in patients with tuberous sclerosis complex (TSC) are inadequately described. As a result, surgeons are faced with a dilemma of predicting which patients with ...

Patients were randomly assigned to receive either Hyftor 0.2% topical gel (n=30) or vehicle (n=32) twice daily to the skin of their face affected with angiofibroma for 12 weeks.